Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
YAE1 divergent transcript refers to RNA molecules transcribed from the promoter region of the YAE1 gene in the *divergent* (antisense or opposite) direction, characteristic of promoter bidirectionality seen in eukaryotic genomes. These molecules are typically *unstable, rapidly degraded*, and largely noncoding. While the phenomenon of divergent transcription is widespread and may play a role in *local regulation of gene expression or chromatin structure*, individual divergent transcripts—including YAE1-DT—are *not considered standalone molecular targets*. The presence and regulation of divergent transcripts can be influenced by sequence-specific transcription factors (like Rap1 in yeast), chromatin remodelers, and local promoter architecture[2][3][4]. If you are seeking structured information for database use or drug discovery, YAE1-DT does not correspond to a canonical target—such as an enzyme, receptor, ion channel, or transcription factor—with established roles in pathophysiology, pharmacology, or therapeutics[2][4].
None (No characterized mechanism of action; pharmacological targeting does not apply.)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on YAE1 divergent transcript.